Diagnostic Performance of a Novel Lipoarabinomannan.

HIV Primary Infection Clinical Trial

— FUJILAM  

Official title:

Diagnostic Performance of a Novel Lipoarabinomannan Test (FujiLAM) to Detect Tuberculosis in HIV-positive Patients in Kenya

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05036694
• Other study ID #: ANRS12429
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 2021
• Est. completion date: December 2022

Study information

• Verified date: July 2021
• Source: Médecins Sans Frontières, Kenya
• Contact: HELENA DR Coordinating Principal Investigator, PhD
• Phone: +32493837895
• Email: Helena.HUERGA[@]epicentre.msf.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Fujifilm SILVAMP TB LAM (FujiLAM; Fujifilm, Tokyo, Japan) is a novel (not commercialized) urine based point-of-care assay to diagnose TB in HIV-positive patients. A first study using urine frozen samples has reported a higher sensitivity of this test over the currently commercialised Alere Determine TB LAM Ag assay (AlereLAM).

Description:

The study aims to assess the performance of a new test called the Fujifilm SILVAMP TB LAM or simply the Fuji-LAM test. The Fuji-LAM test is a test that can be done on urine to look for specific proteins that are produced by the bacteria that causes tuberculosis. This test offers an advantage over the tests that are based on phlegm because most patients can produce urine for testing even when they are very sick. Additionally, this test does not require a complex laboratory set up and it can therefore be used by health workers as they interact with the patient. This study will also look at how the new test compares with an existing test AlereLAM - that is based on similar technology. Initial laboratory-based studies conducted on frozen urine samples show that the new test has better performance than the existing test. This study is different from the first studies because it is being conducted in real life settings rather than in a laboratory.

The study will be conducted at the Homa Bay County Hospital in Kenya. Individuals living with HIV with and without signs and symptoms of TB will be invited to take part. Individuals who agree to participate will be seen by the health workers in the study and will provide samples for testing using the FujiLAM test and other standard tests used to investigate individuals for suspected tuberculosis.

Investigators are also conducting similar studies in other African countries including Uganda, Mozambique and South Africa. This will enable investigators to assess the performance of the test in diverse settings.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 550
• Est. completion date: December 2022
• Est. primary completion date: September 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 15 Years and older

Eligibility

Inclusion Criteria:

• 15 years of age or older

• HIV-positive Group 1: At least one symptom of TB

Group 2:

• Advanced HIV disease (CD4 count less than 200cell/µl or clinical stage III/IV)

• No signs and symptoms of TB

• Signature of the informed consent

Exclusion Criteria:

• Intake of anti-tuberculosis drugs for more than 5 days in the month prior to the consultation except preventive TB treatment.

• Decline to sign informed consent.

Related Conditions & MeSH terms

• HIV Primary Infection
• Tuberculosis

Intervention

Device:
• FUJILAM KIT
Urine based test to detect LAM

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Médecins Sans Frontières, Kenya	Epicentre

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To investigate the diagnostic performance of FujiLAM in ambulatory HIV positive patients.	Proportion of patients with a positive FujiLAM result among patients with microbiologically confirmed TB in ambulatory HIV-positive patients with signs and symptoms of TB (Group 1) and Diagnostic performance of FujiLAM test to detect tuberculosis in HIV-positive patients in Kenya - Protocol v2.3 14 in ambulatory HIV-positive patients with advanced HIV disease and no signs and symptoms of TB (Group 2).	12 months
Secondary	To assess the sensitivity of FujiLAM at different levels of CD4 count.	Proportion of patients with a positive FujiLAM result among patients with probable TB or microbiologically confirmed TB in ambulatory HIV-positive patients with signs and symptoms of TB (Group 1) and in ambulatory HIV-positive patients with advanced HIV disease and no signs and symptoms of TB (Group 2).; Proportion of patients with a positive FujiLAM result among patients with microbiologically confirmed TB and among patients with probable TB or microbiologically confirmed TB by level CD4.; Proportion of patients with a positive AlereLAM among patients with microbiologically confirmed; TB and among patients with probable TB or microbiologically confirmed TB by level of CD4.	12 months